In the high-dose group, patients experienced a mean 0.2-point reduction on the composite Unified Huntington’s Disease Rating Scale (cUHDRS), compared to a 1-point reduction in a control group, translating to an 80% slowing of disease progression. The low-dose group saw a 0.7-point reduction, indicating a 30% slowing. Additionally, levels of neurofilament light protein, a biomarker for neurodegeneration, decreased by 11% across all patients who received AMT-130, compared to a 26% increase in a natural history study.
CMO Walid Abi-Saab highlighted the importance of these findings, noting that the majority of patients had reached the two-year milestone, allowing for robust statistical analysis. This data is particularly promising given the mixed results from previous trials, which had cast doubt on the therapy’s efficacy and led to a significant drop in UniQure’s stock price.
AMT-130, an AAV5 gene therapy delivered directly to the brain, targets exon 1 of the huntingtin gene. Its potential for long-term effects from a one-time administration sets it apart from other treatments. The therapy’s success so far has led to a significant increase in UniQure’s stock, which rose by over 50% following the announcement.
Looking ahead, UniQure is in discussions with the FDA about future trial plans and the possibility of accelerated approval. However, CEO Matt Kapusta acknowledged the potential need for a large-scale Phase 3 trial, which could require a partnership with a larger company due to the substantial financial and time commitments involved. The company plans to meet with the FDA before the end of the year and expects to release 36-month data by mid-2025.
Overall, the latest results from UniQure’s AMT-130 gene therapy trials offer renewed hope for a treatment that can significantly slow the progression of Huntington’s disease, a debilitating neurodegenerative disorder.
https://endpts.com/uniqure-trumpets-mid-stage-data-for-huntingtons-disease-gene-therapy/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
Plasmids GMP Services
AAV GMP Services
